-transparent.png){kind=logo}
A multicenter, open-label clinical trial evaluated the efficacy and tolerability of diflunisal given twice daily and aspirin given four times daily in the long-term treatment of patients with rheumatoid arthritis. Patients who successfully completed a 12-week, double-blind, parallel study comparing diflunisal (500 to 750 mg daily) with aspirin (2.6 to 3.9 gm daily) continued on the same medication in a 40-week, open-label segment of the study. The dosage of diflunisal could be increased to a maximum of 1 gm daily during the open-label phase. Both regimens were effective during the 40-week study. Diflunisal was better tolerated than aspirin as judged by the overall incidence of clinical adverse experiences. Patients treated with diflunisal had significantly fewer adverse experiences involving the digestive system and organs of special sense than did those treated with aspirin.
R A Turner, and
R W Shackleford, and
J P Whipple
October 1987,
The American journal of medicine,
R A Turner, and
R W Shackleford, and
J P Whipple
January 1982,
Pharmacology,
R A Turner, and
R W Shackleford, and
J P Whipple
January 1981,
Scandinavian journal of rheumatology,
R A Turner, and
R W Shackleford, and
J P Whipple
May 1980,
Rheumatology and rehabilitation,
R A Turner, and
R W Shackleford, and
J P Whipple
January 1980,
The Journal of rheumatology. Supplement,
R A Turner, and
R W Shackleford, and
J P Whipple
February 1980,
La Clinica terapeutica,
R A Turner, and
R W Shackleford, and
J P Whipple
January 1987,
Clinical therapeutics,
R A Turner, and
R W Shackleford, and
J P Whipple
January 1975,
Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde,
R A Turner, and
R W Shackleford, and
J P Whipple
February 1974,
British medical journal,
R A Turner, and
R W Shackleford, and
J P Whipple
January 1982,
Reumatizam,
